Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis
- PDF / 2,014,068 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 75 Downloads / 179 Views
SYSTEMATIC REVIEW
Prognostic Value of L‑Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta‑Analysis Chuanmeng Zhang1 · Jie Xu1 · Shanshan Xue2 · Jun Ye1
© Springer Nature Switzerland AG 2020
Abstract Background and Objective The L-type amino acid transporter 1 (LAT1, SLC7A5) is overexpressed in various types of cancer and has been thought to assist cancer progression through its uptake of neutral amino acids. However, the prognostic role of LAT1 in human cancers remains uncharacterized. Therefore, we conducted this meta-analysis to determine the prognostic significance of LAT1 in various cancers. Methods We systematically searched the PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure, and WanFang databases to collect relevant cohort studies investigating the prognostic value of LAT1 expression in patients with cancer. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to clarify the association between the LAT1 expression and the survival of patients with cancer. Odds ratios (ORs) with 95% CIs were calculated to appraise the correlation between LAT1 and the clinicopathological characteristics in patients with cancer. Results A total of 32 eligible articles, including 34 cohorts and 6410 patients, were enrolled in this meta-analysis. Our results demonstrated that high LAT1 expression was significantly associated with poor overall survival (HR = 1.66, 95% CI 1.41–1.96, P 10%
>25% >25%
>25% >25% ≥4
>15
>25% >25% ≥6 >15
36 (41.4) 46 (78.0)
75 (58.6) 35 (47.9) 56 (39.4) 60 (85.7) 8 (6.0) 59 (59.0) 52 (61.2) 81 (87.1) 67 (45.3) 89 (64.0) 32 (64.0) 95 (67.4) 51 (40.5) 51 (52.6) 14 (21.2)
152 (72.4) 93 (59.2) NR 50 (59.5)
39 (35.5) 29 (55.8) 100 (56.2)
268 (18.4)
118 (80.3) 85 (34.7) 34 (37.0) 191 (20.5)
English
English English English English
CSS (U) OS (M)
OS (M), DFS (M) OS (U), PFS (U) OS (M), DFS (U) OS (U), PFS (U) CSS (M) OS (M), PFS (M) OS (M), PFS (M) OS (M), DFS (M) OS (M) OS (M), PFS (M) OS (U), DFS (U) OS (M) OS (M) OS (M), PFS (M) CSS (M)
OS (U) OS (U), DFS (U) OS (M) OS (M), PFS (U)
English English
English English English English English English English Chinese English English English Chinese English English English
English English English English
6
6 7
8 6 8/6 6 8 8 8 8 7 7 6 8 8 7 8
6 8/6
6
7 6 7
6
8 8 8 6
Language Quality
OS (M), DFS (M) English OS (U), PFS (U) English OS (M) English
CSS (U)
OS (M), DFS (M) OS (M), PFS (M) OS (M), PFS (M) CSS (U)
Cut-off value LAT1-high (%) Survival analysis
C. Zhang et al.
BC breast cancer, BDC bile duct adenocarcinomas, BTC biliary tract cancer, CA cutaneous angiosarcoma, CCA cholangiocarcinoma, CM cutaneous melanoma, CRC colorectal cancer, CSS cancer-specific survival, DFS disease-free survival, ESCC esophageal squamous cell carcinoma, GC gastric carcinomas, HCC hepatocellular carcinoma, HSCC hypopharyngeal squamous cell carcinoma, IHC immunohistochemistry, LAT1 L-type amino acid transporter 1, LC lung cancer, LSCC laryngeal squamous cell carcinoma, M multivari
Data Loading...
